Suppr超能文献

异基因造血干细胞移植后腺病毒肺炎的临床表现、预后因素和转归。

Clinical manifestations, prognostic factors, and outcomes of adenovirus pneumonia after allogeneic hematopoietic stem cell transplantation.

机构信息

Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.

Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.

出版信息

Virol J. 2024 May 14;21(1):110. doi: 10.1186/s12985-024-02383-1.

Abstract

BACKGROUND

Severe pneumonia is one of the most important causes of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Adenovirus (ADV) is a significant cause of severe viral pneumonia after allo-HSCT, and we aimed to identify the clinical manifestations, prognostic factors, and outcomes of ADV pneumonia after allo-HSCT.

METHODS

Twenty-nine patients who underwent allo-HSCT at the Peking University Institute of Hematology and who experienced ADV pneumonia after allo-HSCT were enrolled in this study. The Kaplan-Meier method was used to estimate the probability of overall survival (OS). Potential prognostic factors for 100-day OS after ADV pneumonia were evaluated through univariate and multivariate Cox regression analyses.

RESULTS

The incidence rate of ADV pneumonia after allo-HSCT was approximately 0.71%. The median time from allo-HSCT to the occurrence of ADV pneumonia was 99 days (range 17-609 days). The most common clinical manifestations were fever (86.2%), cough (34.5%) and dyspnea (31.0%). The 100-day probabilities of ADV-related mortality and OS were 40.4% (95% CI 21.1%-59.7%) and 40.5% (95% CI 25.2%-64.9%), respectively. Patients with low-level ADV DNAemia had lower ADV-related mortality and better OS than did those with high-level (≥ 10 copies/ml in plasma) ADV DNAemia. According to the multivariate analysis, high-level ADV DNAemia was the only risk factor for intensive care unit admission, invasive mechanical ventilation, ADV-related mortality, and OS after ADV pneumonia.

CONCLUSIONS

We first reported the prognostic factors and confirmed the poor outcomes of patients with ADV pneumonia after allo-HSCT. Patients with high-level ADV DNAemia should receive immediate and intensive therapy.

摘要

背景

重症肺炎是异基因造血干细胞移植(allo-HSCT)后最重要的死亡原因之一。腺病毒(ADV)是 allo-HSCT 后严重病毒性肺炎的重要病因,本研究旨在明确 allo-HSCT 后 ADV 肺炎的临床表现、预后因素和结局。

方法

本研究纳入 29 例在北京大学血液病研究所接受 allo-HSCT 且发生 ADV 肺炎的患者。采用 Kaplan-Meier 法估计总生存率(OS)。通过单因素和多因素 Cox 回归分析评估 ADV 肺炎后 100 天 OS 的潜在预后因素。

结果

allo-HSCT 后 ADV 肺炎的发生率约为 0.71%。从 allo-HSCT 到 ADV 肺炎发生的中位时间为 99 天(范围 17-609 天)。最常见的临床表现为发热(86.2%)、咳嗽(34.5%)和呼吸困难(31.0%)。ADV 相关死亡率和 OS 的 100 天概率分别为 40.4%(95%CI 21.1%-59.7%)和 40.5%(95%CI 25.2%-64.9%)。低水平 ADV DNAemia 的患者 ADV 相关死亡率和 OS 均低于高水平 ADV DNAemia(血浆中≥10 拷贝/ml)。多因素分析显示,高水平 ADV DNAemia 是重症监护病房入住、有创机械通气、ADV 相关死亡率和 ADV 肺炎后 OS 的唯一危险因素。

结论

我们首次报道了 allo-HSCT 后 ADV 肺炎的预后因素,并证实患者预后不良。高水平 ADV DNAemia 的患者应立即接受强化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b071/11094961/880f1497e5c1/12985_2024_2383_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验